Overall, the KMT2A-rearranged AML patients have significantly high levels of BCL-2, phospho-BCL-2 S70, and MCL-1 (Figure 2A; **p < 0.01, ***p < 0.001). This evidence concerns the gene MCL1 and acute myeloid leukemia.